A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

These glasses allow people with macular degeneration to see complete objects by banishing pesky blind spots using dozens of ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Germany’s Formycon and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted ...

Regulatory ApprovalFormycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / 06:30 CET/CESTThe issuer is solely ...

Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...